Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis
Por:
Suarez-Cuartin G., Smith A., Abo-Leyah H., Rodrigo-Troyano A., Perea L., Vidal S., Plaza V., Fardon T.C., Sibila O., Chalmers J.D.
Publicada:
1 ene 2017
Resumen:
Background Identification of chronic Pseudomonas aeruginosa (PA) infection is important in the management of bronchiectasis, but requires repeated sputum sampling. We hypothesized that serum anti-PA IgG antibodies could diagnose chronic PA infection at a single visit. Methods Clinically stable bronchiectasis patients were studied prospectively. Chronic PA infection was defined as 2 or more positive sputum samples at least 3 months apart and/or failure to clear PA following eradication treatment. Baseline serum anti-PA IgG was determined by a validated ELISA kit. Results A total of 408 patients were included. Sixty of them (14.7%) had chronic PA infection and had higher anti-PA IgG levels (median 6.2 vs. 1.3 units, p < 0.001). Antibody levels showed direct significant correlations with exacerbation frequency, the bronchiectasis severity index and sputum inflammatory markers. Fifty-seven patients with chronic PA infection had a positive test, giving 95% sensitivity, 74.4% specificity and AUROC of 0.87. During follow-up, 38 patients had a new PA isolation. Eradication at 12 months was achieved in 89.5% of subjects with a negative antibody test and 15.8% of patients with a positive test. Conclusions Anti-PA IgG test is highly accurate to detect chronic PA infection in bronchiectasis patients. In addition, it may be a marker of disease severity and treatment response. © 2017
Filiaciones:
Suarez-Cuartin G.:
Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Institut d´Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain
Smith A.:
Tayside Respiratory Research Group, University of Dundee, Dundee, United Kingdom
Abo-Leyah H.:
Tayside Respiratory Research Group, University of Dundee, Dundee, United Kingdom
Rodrigo-Troyano A.:
Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Institut d´Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain
Perea L.:
Institut d´Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain
Vidal S.:
Institut d´Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain
Plaza V.:
Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Institut d´Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain
Fardon T.C.:
Tayside Respiratory Research Group, University of Dundee, Dundee, United Kingdom
Sibila O.:
Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Institut d´Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain
Chalmers J.D.:
Tayside Respiratory Research Group, University of Dundee, Dundee, United Kingdom
Bronze
|